Morgan Stanley’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-540
| Closed | -$394 | – | 8144 |
|
|
2023
Q4 | $394 | Buy |
540
+270
| +100% | +$229 | ﹤0.01% | 7302 |
|
|
2023
Q3 | $303 | Hold |
270
| – | – | ﹤0.01% | 7357 |
|
|
2023
Q2 | $364 | Sell |
270
-1,199
| -82% | -$1.52K | ﹤0.01% | 7404 |
|
|
2023
Q1 | $1.56K | Sell |
1,469
-31
| -2% | -$59 | ﹤0.01% | 7283 |
|
|
2022
Q4 | $3.52K | Buy |
1,500
+31
| +2% | +$78 | ﹤0.01% | 7241 |
|
|
2022
Q3 | $6K | Buy |
1,469
+315
| +27% | +$1.72K | ﹤0.01% | 7235 |
|
|
2022
Q2 | $5K | Buy |
1,154
+3
| +0.3% | +$16 | ﹤0.01% | 7432 |
|
|
2022
Q1 | $10K | Sell |
1,151
-1
| -0.1% | -$10 | ﹤0.01% | 7426 |
|
|
2021
Q4 | $13K | Buy |
1,152
+1
| +0.1% | +$14 | ﹤0.01% | 7404 |
|
|
2021
Q3 | $20K | Sell |
1,151
-877
| -43% | -$14.5K | ﹤0.01% | 7109 |
|
|
2021
Q2 | $38K | Buy |
2,028
+1,903
| +1,522% | +$36.3K | ﹤0.01% | 6790 |
|
|
2021
Q1 | $3K | Buy |
125
+119
| +1,983% | +$3.57K | ﹤0.01% | 7246 |
|
|
2020
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 7301 |
|
|
2020
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 6994 |
|
|
2020
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 6915 |
|
|
2020
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 6946 |
|
|
2019
Q4 | $1K | Hold |
6
| – | – | ﹤0.01% | 6628 |
|
|
2019
Q3 | $2K | Hold |
6
| – | – | ﹤0.01% | 6524 |
|
|
2019
Q2 | $4K | Hold |
6
| – | – | ﹤0.01% | 6384 |
|
|
2019
Q1 | $7K | Sell |
6
-1
| -14% | -$1.16K | ﹤0.01% | 6280 |
|
|
2018
Q4 | $8K | Sell |
7
-1
| -13% | -$1.45K | ﹤0.01% | 6229 |
|
|
2018
Q3 | $12K | Sell |
8
-2
| -20% | -$2.95K | ﹤0.01% | 6279 |
|
|
2018
Q2 | $13K | Buy |
10
+2
| +25% | +$11K | ﹤0.01% | 6257 |
|
|
2018
Q1 | $77K | Hold |
8
| – | – | ﹤0.01% | 5779 |
|
|
2017
Q4 | $115K | Sell |
8
-5
| -38% | -$116K | ﹤0.01% | 5602 |
|
|
2017
Q3 | $341K | Sell |
13
-2
| -13% | -$61.5K | ﹤0.01% | 5096 |
|
|
2017
Q2 | $762K | Buy |
15
+3
| +25% | +$164K | ﹤0.01% | 4566 |
|
|
2017
Q1 | $885K | Sell |
12
-1
| -8% | -$80.8K | ﹤0.01% | 4472 |
|
|
2016
Q4 | $1.03M | Buy |
13
+6
| +86% | +$536K | ﹤0.01% | 4441 |
|
|
2016
Q3 | $915K | Sell |
7
-1
| -13% | -$125K | ﹤0.01% | 4106 |
|
|
2016
Q2 | $849K | Hold |
8
| – | – | ﹤0.01% | 4101 |
|
|
2016
Q1 | $1.06M | Buy |
8
+3
| +60% | +$322K | ﹤0.01% | 3884 |
|
|
2015
Q4 | $708K | Buy |
5
+1
| +25% | +$149K | ﹤0.01% | 4300 |
|
|
2015
Q3 | $698K | Hold |
4
| – | – | ﹤0.01% | 4385 |
|
|
2015
Q2 | $1.17M | Buy |
+4
| New | +$1.06M | ﹤0.01% | 4077 |
|
Other funds holding NVIV
Morgan Stanley's NVIV Position: Q1 2024 in Review
Morgan Stanley sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 540 shares — an estimated $394 sold.
Morgan Stanley first reported a position in NVIV in Q2 2015 and held it in 35 quarters. The position peaked at $1.17M in Q2 2015. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.
- Morgan Stanley reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
- Morgan Stanley sold 540 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $394.
- Morgan Stanley first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 35 quarters.
- Morgan Stanley's InVivo Therapeutics Holdings Corp position peaked at $1.17M in Q2 2015.
- 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.
Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.